In Reply: While we agree with Dr Köhler
and colleagues that the CLASS trial supports the hypothesis that COX-2–specific
inhibitors will produce fewer ulcers and ulcer complications than conventional
NSAIDs, we disagree that the data suggest the possibility that celecoxib interferes
with healing of aspirin-induced GI mucosal lesions. A prior study1 has found that the relative risk of an ulcer complication
in aspirin users vs nonaspirin users is approximately the same as the relative
risk of an ulcer complication in aspirin users receiving celecoxib vs nonaspirin
users receiving celecoxib that we reported.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 3
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.